Open AccessRelationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?
Author(s) -
Umberto Malapelle,
Antônio Rossi,
Emilio Bria
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.08.99
Subject(s) - osimertinib , medicine , t790m , lung cancer , tyrosine kinase , somatic cell , epidermal growth factor receptor , oncology , tyrosine kinase inhibitor , protein kinase domain , non small cell lung cancer (nsclc) , cancer , gene , receptor , gefitinib , genetics , biology , mutant , erlotinib , a549 cell
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom